All GLG News Analyses Filed Under: Oncology

We can now determine with genetic tests who is at risk for developing PC. ProActive Genetics. The more genetic variants found, the greater the risk of PC. 4 or 5 variants increased ones risk x 4.5.

These lessons are valuable for considering new cancer research findings.     Just ask Genentech. Symbol: DNA

Sirolimus has shown activity in shrinking benign tumors associated with tuberous sclerosis......opens the door for further exploration alone and combo in other mTOR driven disorders

Targeting this protein MAY offer a therapeutic alternative or "add on" in GI malignancies.

In 2 small studies, Wyeth's M-tor inhibitor, Sirolimus, decraesed size of benign tumors in patients with Tuberous sclerosis and even improved lung function in one study. Sirolimus may have a role outside renal cancer in hematological malignancies , sracomas, as well as melanoma.

Amgen hit hard by recent ESA reimbursement requirements Amgen Has Neulasta, but is this a sure winner Amgen has no dynamite in near future

Sirolimus reduces the size of "benign" tumors found in tuberous sclerosis.

Amgen's ESA's ( Aranesp and Epgen) use is expected to decline amongst oncologists and nephrologists even if Medicare revises its guidelines, which is in doubt. Osteoporosis is a crowded market with already many approved drugs. Amgen's denosumab which lacks superiority data to these agents is unliokely...

Agendia announced the completion of a clinical study demonstrating the value of its Mamaprint(R) breast cancer prognosis test in postmenopausal women.  Agendia believes that this data will enable it to file for expanded claims with the FDA for Mamaprint(R).  Expanded claims for Agendia's DNA...

Exilexis XL-184 is an oral small molecules that target many receptor tyrosinae kinases ( RTK's) like MET, RET and VEGFR , which is being tested in Phase I/II trial with and without  Tarceva in patients with NSCLC. The fact that early phase trials showed no incraesed cardiac side...